Scientists hunt for clues to catch ALS before symptoms start
NCT ID NCT07213440
First seen Jun 24, 2026 · Last updated Jul 08, 2026 · Updated 4 times
Summary
This study aims to find early markers for ALS by analyzing blood, urine, spinal fluid, tears, and smell tests in 60 people. It includes those with ALS gene mutations but no symptoms, early ALS patients, and healthy controls. The goal is to enable earlier diagnosis and better treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a way to diagnose ALS earlier, which may improve treatment timing and outcomes.
- What could go wrong
- This is an observational study with only 60 participants, so results may not apply to everyone. It focuses on finding markers, not testing a treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Tours
RECRUITINGTours, France, 37000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Custom-Made genetic drug slow ALS?
- Can a One-Time gene shot calm inflammation in ALS?
- Can filtering the blood slow ALS in people with a troubling antibody?
- Blood test may slash ALS diagnosis time from months to days
- Custom gene silencer takes aim at a rare form of ALS
- Could a gentle brain ZAP help ALS patients breathe easier?